Egypt has successfully secured support of the Africa Centers for Disease Control and Prevention (Africa CDC) to establish a regional biomanufacturing hub for North Africa.
The selection reflects Cairo’s commitment to advancing pharmaceutical manufacturing, particularly vaccine production, and strengthening biotechnology research, Minister of Higher Education and Scientific Research Ayman Ashour said in a statement Saturday 8/2/2025.
The achievement aligns with Egypt’s strategy to enhance health security both domestically and across Africa, aiming for vaccine self-sufficiency, he added.
The selection of Egypt as the headquarters for the Regional Center for Capacity Building in Biomanufacturing (RCCN), in partnership with Morocco, follows the approval of Egypt’s proposal, submitted by the Unified Procurement Authority (UPA) under the Egyptian Vaccine Manufacturers Alliance (EVMA).
EVMA comprises six key entities, namely the Unified Procurement Authority (UPA), the Academy of Scientific Research and Technology, the Egyptian Drug Authority, the Faculty of Pharmacy – Ain Shams University, the Faculty of Pharmacy – Cairo University, alongside leading vaccine manufacturers, including VACSERA, Biogeneric Pharma, Egyptian Vaccine City, GenVax, and Eva Pharma.
This initiative marks a significant step towards positioning Egypt as a biomanufacturing leader in Africa, reinforcing regional health security and vaccine production capabilities, the statement concluded.
